GSK/Theravance Seek to Expand Marketing of COPD Inhaler

GlaxoSmithKline and Theravance are seeking approval in the U.S. to market their COPD inhaler Breo Ellipta (fluticasone furoate/vilanterol) for patients with asthma as well. The companies said they have filed a supplemental New Drug Application with the FDA for the inhaled corticosteroid/long-acting beta2 agonist as a treatment for asthma in patients aged 12 years and over.

According to a New York Times article, despite medical advances more than half of patients with asthma continue to experience poor control and significant symptoms, and the firms will be hoping that their product will help address some of this unmet need, while giving sales a nice little boost at the same time. Read the full story